Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069408 | 0.90 | EPHA2 (0.41) | EPHA2GPR119ERBB2EPHB4USP2 | |
| SCHEMBL26923813 | 0.78 | GPR119 (0.36) | GPR119USP2SMN1; SMN2JAK2JAK1 | |
| SCHEMBL21069485 | 0.78 | EPHA2 (0.52) | EPHA2GPR119ERBB2EPHB4USP2 | |
| SCHEMBL306376 | 0.77 | JAK2 (0.46) | EPHA2GPR119ERBB2EPHB4SMN1; SMN2 | |
| SCHEMBL306377 | 0.77 | JAK2 (0.46) | EPHA2GPR119ERBB2EPHB4SMN1; SMN2 | |
| SCHEMBL969537 | 0.77 | JAK2 (0.46) | EPHA2GPR119ERBB2EPHB4SMN1; SMN2 | |
| SCHEMBL23860226 | 0.77 | USP2 (0.43) | EPHA2ERBB2EPHB4USP2SMN1; SMN2 | |
| SCHEMBL1551950 | 0.76 | USP2 (0.43) | EPHA2GPR119ERBB2EPHB4USP2 | |
| SCHEMBL1551948 | 0.76 | USP2 (0.43) | EPHA2GPR119ERBB2EPHB4USP2 | |
| SCHEMBL3237397 | 0.75 | DRD4 (0.52) | GPR119SMN1; SMN2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHA2 780/4885GPR119 2426/4885ERBB2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.